Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: a review of clinical trials

An unfortunate subset of hypertensive patients develops resistant hypertension in which optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control blood pressure. Patients with resistant hypertension represent a high-risk and difficult-to-treat group, and such pati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sara Abdulrahman Alomar, Sarah Ali Alghabban, Hadeel Abdulaziz Alharbi, Mehad Fahad Almoqati, Yazid Alduraibi, Ahmed Abu-Zaid
Formato: article
Lenguaje:EN
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2021
Materias:
R
Acceso en línea:https://doaj.org/article/5afe9e6fa7fa466cbd872672f3cc700a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!